The U.S. House of Representatives voted late Tuesday to passan FDA fees package, which is expected to collect $330 millionover five years.

William Small, executive director of the Association ofBiotechnology Companies, told BioWorld that the bill will nextgo before the U.S. Senate with ABC amendments. The ABC seeksa one-year exemption from all fees for companies with fewerthan 500 employees filing their first NDA, or for productsdesignated by the FDA as an orphan drug.

Small said he expects the Senate to vote on the bill before theend of the month.

(c) 1997 American Health Consultants. All rights reserved.

No Comments